Health-related quality of life (HRQOL) in young children with haemophilia B treated with the novel long-acting nonacog beta pegol recombinant factor IX

¹CHCMN Hemophilia and Thrombosis Center Children's Hospital and Clinics of Minnesota, USA;

²Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy;

³Haemophilia, Haemostasis and Thrombosis Centre, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Hampshire, UK;

⁴Rural and Northern Health, Laurentian University, Sudbury, Canada;

⁵Novo Nordisk A/S, Bagsvaerd, Denmark;

⁶Mapi Patient-Centered Outcomes, Lyon, France; and

⁷Divisions of Haematology/Oncology, Department of Paediatrics and Research Institute, Hospital for Sick Children, University of Toronto, ON, Canada